Tempest TherapeuticsTPST 32 Return-on-Tangible-Equity is -2,958.18% as of Mar. 2026. GuruFocus rates TPST with a GF Score™ of 32/100. The stock has 1 warning sign investors should review. Among 1,200 Biotechnology companies, Tempest Therapeutics ranks worse than 95.5% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Tempest Therapeutics's annualized net income for the quarter that ended in Mar. 2026 was $-110.78 Mil. Tempest Therapeutics's average shareholder tangible equity for the quarter that ended in Mar. 2026 was $3.75 Mil. Therefore, Tempest Therapeutics's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was -2,958.18%.
The historical rank and industry rank for Tempest Therapeutics's Return-on-Tangible-Equity or its related term are showing as below:
TPST'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -620.08 Med: -157.03 Max: -131.42
Current: -620.08
During the past 6 years, Tempest Therapeutics's highest Return-on-Tangible-Equity was -131.42%. The lowest was -620.08%. And the median was -157.03%.
TPST's Return-on-Tangible-Equity is ranked worse than 95.5% of 1200
companies
in the Biotechnology industry
Industry Median: -42.435
vs TPST: -620.08
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Tempest Therapeutics Return-on-Tangible-Equity Related Terms
Tempest Therapeutics Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Tempest Therapeutics's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPST vs HOWL, INTI, GTBP: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Tempest Therapeutics's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tempest Therapeutics Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tempest Therapeutics's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Tempest Therapeutics's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -2,958.18% mean?
Tempest Therapeutics (TPST) has a Return-on-Tangible-Equity of -2,958.18% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Tempest Therapeutics and its competitors. According to the industry distribution chart, Tempest Therapeutics ranks #1146 out of 1200 companies in the Biotechnology industry, placing it in the top 95.5%.
Is Tempest Therapeutics' Return-on-Tangible-Equity too high?
Tempest Therapeutics' current Return-on-Tangible-Equity is -2,958.18%. Based on the distribution chart, Tempest Therapeutics ranks #1146 out of 1200 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Tempest Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Tempest Therapeutics' Return-on-Tangible-Equity compare to HOWL and INTI?
According to the Biotechnology industry distribution chart, Tempest Therapeutics ranks #1146 out of 1200 companies for Return-on-Tangible-Equity. This places Tempest Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Tempest Therapeutics and its competitors. Tempest Therapeutics's current Return-on-Tangible-Equity is -2,958.18%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tempest Therapeutics stock overvalued right now?
Tempest Therapeutics (TPST) has a current Return-on-Tangible-Equity of -2,958.18%. The current Return-on-Tangible-Equity is -2,958.18%. Tempest Therapeutics' overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Tempest Therapeutics (TPST), the current Return-on-Tangible-Equity is -2,958.18% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.
32GF Score
Get the complete analysis for TPST
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPST has been successfully added to your 
